| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
SPD-304 is a novel, potent and selective inhibitor of tumor necrosis factor α (TNFα) with an IC50 of 22 µM for preventing binding to the TNF Receptor 1 (TNFR1). Angiotensin (Ang) II/Ang II receptor type 1 (AT1) and tumor necrosis factor (TNF)-α play critical roles in neuropathic pain and nociception, respectively.
| Targets |
TNFα (IC50 = 22 µM)
|
|---|---|
| ln Vitro |
SPD304 (2 μM) significantly rescues the survivability of aHSCs, reduces the production of lipid hydroxides, and increased intracellular GSH. The co-treatment of GA (75 μM) and SPD304 (2 μM) downregulates TRADD almost 2-fold (w/o inhibitor vs. w/ inhibitor) and pRIP3 1.4-fold compared to GA alone, and promotes caspase 8 activation[4].
|
| ln Vivo |
SPD304 cannot be used in vivo due to its high toxicity[3].
|
| References |
| Molecular Formula |
C32H32F3N3O2
|
|---|---|
| Molecular Weight |
547.6106
|
| Exact Mass |
547.244
|
| Elemental Analysis |
C, 70.19; H, 5.89; F, 10.41; N, 7.67; O, 5.84
|
| CAS # |
869998-49-2
|
| Related CAS # |
SPD304 dihydrochloride;1049741-03-8
|
| PubChem CID |
5327044
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
589.2±50.0 °C at 760 mmHg
|
| Flash Point |
310.2±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
8.23
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(CN(CCN(CC2C3C(=CC=CC=3)N(C3C=C(C(F)(F)F)C=CC=3)C=2)C)C)=COC2C1=CC(C)=C(C)C=2
|
| InChi Key |
JZNXLPPJRFFECJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H32F3N3O2/c1-21-14-28-30(15-22(21)2)40-20-24(31(28)39)18-37(4)13-12-36(3)17-23-19-38(29-11-6-5-10-27(23)29)26-9-7-8-25(16-26)32(33,34)35/h5-11,14-16,19-20H,12-13,17-18H2,1-4H3
|
| Chemical Name |
6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one
|
| Synonyms |
SPD-304; SPD 304; SPD304
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Water: ~100 mg/mL (~182.6 mM)
DMSO: ~50 mg/mL (~91.3 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (2.28 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8261 mL | 9.1306 mL | 18.2612 mL | |
| 5 mM | 0.3652 mL | 1.8261 mL | 3.6522 mL | |
| 10 mM | 0.1826 mL | 0.9131 mL | 1.8261 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
